Compare The Coca-Cola Co K (KO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Novo Nordisk A/S — how do they compare? The Coca-Cola Co K trades at $86.35 (market cap $372.08B), while Novo Nordisk A/S trades at $46.02 (market cap $207.85B). The key difference: The Coca-Cola Co K is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| KO | NVO | |
|---|---|---|
Market Cap | $372.08B | $207.85B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $63.98 |
52-Week Low | $65.67 | $35.29 |
Enterprise Value | $399.26B | $222.55B |
Dividend Yield | 2.45% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.87, down 0.21% today, with a bullish technical signal supported by moving averages and RSI near 69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
KO offers a solid dividend history with 64 consecutive years of increases, but faces risks from regional demand divergence and high debt. Analysts are bullish with a $95.83 price target, implying 10% upside, though valuation multiples like P/E of 25.97 suggest premium pricing relative to peers.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
